Thomas R. Staab II Sells 14,087 Shares of BioCryst Pharmaceuticals, Inc. (BCRX) Stock
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) insider Thomas R. Staab II sold 14,087 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $8.12, for a total transaction of $114,386.44. Following the transaction, the insider now directly owns 138,055 shares in the company, valued at approximately $1,121,006.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
BioCryst Pharmaceuticals stock opened at $7.70 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.25 and a current ratio of 1.25. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.25 and a 1 year high of $8.31.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.03). The company had revenue of $1.45 million for the quarter, compared to the consensus estimate of $2.53 million. BioCryst Pharmaceuticals had a negative net margin of 428.00% and a negative return on equity of 145.89%. As a group, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.98 earnings per share for the current year.
Several equities research analysts have recently issued reports on the stock. BidaskClub cut shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. JMP Securities lifted their price objective on shares of BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, September 5th. HC Wainwright reiterated a “buy” rating and set a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, August 13th. They noted that the move was a valuation call. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $7.75 price objective on the stock in a research report on Tuesday, October 9th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $8.50 price objective on shares of BioCryst Pharmaceuticals in a research report on Thursday, August 9th. One analyst has rated the stock with a sell rating, three have given a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $9.89.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Recommended Story: Stock Symbols, CUSIP and Other Stock Identifiers
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.